 |
|
|
Breastfeeding Guidelines Following Radiopharmaceutical
Administration
An article in the European Journal of Nuclear Medicine combined
data on the radioactivity secreted in breast milk for most nuclear medicine
procedures. Recommendation were made for the interruption of breastfeeding
in patients having a nuclear medicine investigation. These are summarized
here:
- Breastfeeding should be noted in the patient history from the
attending physician.
- The nuclear medicine technologist should ask about the patient's
breastfeeding status and notify the nuclear physician when a patient is
breastfeeding.
- Breastfeeding should be interrupted for the time radioactivity is
known at appear in breast milk.
- Close contact with an infant should be restricted to 5 hours in 24
hours for Tc-99m MIBI, Tc-99m labeled RBCs and I-131 (>3mCi) whether or
not the mother is breastfeeding.
Radiopharmaceutical Recommendation
| Tc-99m labeled DMSA, MDP, HDP, DISIDA, SC, MIBI, and Gluceptate, & In-111 WBC
|
Interruption of 4 hours |
| Tc-99m labeled MAA, PYP, DTPA, and RBCs |
Interruption of 12 hours |
| 99mTcO4-, I-123, I-131 hippurate |
Interruption of 24 hours |
| T1-201, Ga-67, I-131 |
Breastfeeding Contraindicated |
References:
Harding LK, Bossuyt A, Pellet S, Reiners C, Talbot JN. "Recommendations
for nuclear medicine physicians regarding breastfeeding mothers."
European J Nucl Med.1995; 22:BP.
|
